BriaCell to Present Preclinical Data on Innovative Cancer Vaccine at SITC 2025
BriaCell Therapeutics Corp. is set to unveil preclinical data on its innovative cancer vaccine, Bria-OTS+, at the prestigious Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting. The event will take place on Friday, November 7, 2025, at the Gaylord National Resort and Convention Center in National Harbor, MD.
The presentation, titled 'Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance', will highlight the promising preclinical results of Bria-OTS+. This novel approach combines trained innate immunity and adaptive memory, potentially offering a new strategy in the fight against cancer.
The poster presentation will be led by a representative from BriaCell Therapeutics Corp., with the company's President & CEO, Dr. William V. Williams, serving as the primary contact.
Following the presentation, a copy of the poster will be made available on the BriaCell Therapeutics Corp. website, allowing interested parties to delve deeper into the innovative preclinical data of Bria-OTS+. This presentation at SITC 2025 underscores BriaCell's commitment to advancing cancer immunotherapy and potentially redefining cancer vaccine strategies.
